Immunology and Microbiology
Agonist
10%
Amino Terminal Sequence
5%
Antiviral Activity
6%
Blood Plasma
19%
Breakthrough Infection
14%
CC Chemokine Receptors
9%
CCR5
8%
CD4
8%
CD4 Lymphocyte Count
6%
Cell Surface
11%
Chemokine Receptor
13%
Cladistics
17%
CXCR4
15%
Cytotoxic T-Cell
9%
Dendritic Cell
6%
Disease Burden
10%
Drug Resistance
11%
Dynamics
14%
Gamma Chemokine
7%
HBsAg
6%
Hepatitis B
9%
Hepatitis B Antigen
6%
Hepatitis B Virus
8%
Hepatitis C
12%
Hepatitis C Virus
18%
Human Immunodeficiency Virus
26%
Human Immunodeficiency Virus 1
100%
Human Immunodeficiency Virus Infection
9%
Human Immunodeficiency Virus Type 1 Subtype B
6%
Human Immunodeficiency Virus Type 1 Subtype C
9%
Humanized Mouse
9%
Immunity
14%
Immunology
10%
Integrase
7%
Molecular Epidemiology
6%
Natural Killer Cell
13%
Neutralization
10%
Neutralizing Antibody
7%
Omicron Coronavirus Variant
15%
Phylogeny
14%
Prevalence
25%
Protein Expression
5%
Reverse Transcriptase
6%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
T Cell
10%
T-Helper Cell
20%
Target Cell
6%
Viral Load
31%
Viremia
5%
Virus Infectivity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anti-Human Immunodeficiency Virus
6%
Antiviral Activity
7%
Antiviral Therapy
7%
Antivirus Agent
24%
Beta Chemokine
5%
Cassia
9%
Chemokine Receptor
10%
Chronic Hepatitis C
9%
Disease
19%
Drug Resistance
18%
Efavirenz
5%
Elimination
25%
Hepatitis B
16%
Hepatitis B Virus
19%
Hepatitis C
31%
Hepatitis C Virus
38%
HIV
97%
HIV Drug Resistance
5%
Human Immunodeficiency Virus 1
9%
Human Immunodeficiency Virus Infection
9%
Infection
47%
Integrase
13%
Lamivudine
11%
Lopinavir Plus Ritonavir
8%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Nucleic Acid
9%
Nucleocapsid Protein
9%
Prevalence
50%
Raltegravir
6%
Receptor
5%
Viremia
7%
Virus Hepatitis
16%
Zidovudine
6%
Medicine and Dentistry
Antiretroviral Therapy
18%
Antiviral Therapy
12%
Antivirus Agent
15%
COVID-19
10%
Disease Burden
8%
Drug Resistance
18%
Drug Use
9%
Harm Reduction
5%
Hepatitis B
19%
Hepatitis B Virus
19%
Hepatitis C
35%
Hepatitis C Virus
45%
Hepatitis Virus
14%
HIV Drug Resistance
5%
HIV/AIDS
8%
Human Immunodeficiency Virus
75%
Human Immunodeficiency Virus Infection
11%
Human Immunodeficiency Virus Type 1 Subtype B
5%
Infection
59%
Integrase
11%
Liver Disease
9%
Molecular Epidemiology
6%
Multidrug Resistance
5%
Odds Ratio
7%
Phylogeny
7%
Polymerase
5%
Prevalence
39%
Public Health
11%
Resistance Mutation
7%
Ritonavir
5%
Viremia
11%